View Older Stories View More Recent Stories

Nov 23, 2020 06:47AM Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
Nov 23, 2020 06:45AM Merck (MRK) to Acquire OncoImmune for $425 Million
Nov 23, 2020 06:45AM Merck to Acquire OncoImmune
Nov 17, 2020 01:25PM Merck Announces First-Quarter 2021 Dividend
Nov 16, 2020 06:46AM Merck (MRK) Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Nov 16, 2020 06:45AM Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Nov 13, 2020 04:11PM FDA Approves Merck’s (MRK) KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10)
Nov 13, 2020 04:10PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express P
Nov 10, 2020 06:49AM Merck (MRK) Announces KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement in PFS, OS and ORR Versus Sunitinib as First-Line Treatment for Patients with RCC
Nov 10, 2020 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Ve
Nov 9, 2020 04:58PM Merck (MRK) Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic NSCLC To Stop for Futility
Nov 9, 2020 04:10PM Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Sto
Nov 5, 2020 06:45AM LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Nov 5, 2020 06:45AM LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
Nov 5, 2020 06:32AM Merck (MRK) to Buy VelosBio for $2.75 Billon
Nov 5, 2020 06:30AM Merck to Acquire VelosBio
Oct 27, 2020 06:45AM Merck Announces Third-Quarter 2020 Financial Results
Oct 22, 2020 08:00AM Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
Oct 21, 2020 06:45AM Merck to Present New Data from its Extensive Infectious Diseases and Vaccines Pipeline and Portfolio During IDWeek 2020
Oct 20, 2020 06:45AM Merck (MRK) Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Investigational 15-valent Pneumococcal Conjugate Vaccine
Oct 20, 2020 06:45AM Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
Oct 16, 2020 02:00PM Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUD
Oct 15, 2020 06:46AM Merck (MRK) Announces FDA Approves Expanded Indication for KEYTRUDA in Adult Patients With R/R Classical Hodgkin Lymphoma
Oct 15, 2020 06:45AM FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Oct 14, 2020 08:00AM Merck Issues 2019/2020 Corporate Responsibility Report
Oct 8, 2020 08:30AM MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Production Plant
Oct 8, 2020 06:50AM Merck (MRK) Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Oct 8, 2020 06:45AM Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Oct 6, 2020 01:00PM MilliporeSigma Inaugurates New, Upgraded Onsite Industrial Water Treatment Plant
Oct 2, 2020 08:06AM Merck (MRK) Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Oct 2, 2020 08:00AM Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Oct 1, 2020 06:45AM Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
Oct 1, 2020 06:30AM Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27
Sep 28, 2020 06:45AM Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
Sep 21, 2020 12:32PM Merck's (MRK) KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Sep 21, 2020 12:30PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Sep 21, 2020 08:33AM Merck (MRK) Reports First-Line Treatment with KEYTRUDA (pembrolizumab) Doubled 5-Yr Survival Rate (31.9%) vs. Chemotherapy (16.3%) in Certain Patients w/ Metastatic NSCLC & PD-LI Turmors
Sep 21, 2020 08:25AM First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose
Sep 21, 2020 06:47AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 mCRPC
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sep 20, 2020 12:30PM LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abira
Sep 20, 2020 12:30PM LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
Sep 20, 2020 10:20AM Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
Sep 20, 2020 08:25AM Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 19, 2020 10:20AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Sep 18, 2020 06:46AM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA Improved Median PFS to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:45AM LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:02AM Pfizer (PFE), Merck (MRK) Biopharmaceutical Business, EMD Serono, Reports Publication of BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results
Sep 18, 2020 03:00AM BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
View More Recent Stories View Older Stories